Immune evasion proteins gpUS2 and gpUS11 of human cytomegalovirus incompletely protect infected cells from CD8 T cell recognition

Virology

Volumn 391, Issue 1, 2009, Pages 5-19

  Besold, K ^a   Wills, M ^b   Plachter, B ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

CTL; Cytomegalovirus; IE1; Immune evasion; MHC class I; pp65; US11; US2

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; GLYCOPROTEIN; GLYCOPROTEIN GP US11; GLYCOPROTEIN GP US2; HLA A2 ANTIGEN; HLA B7 ANTIGEN; IE1 PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CD4+ T LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; SKIN FIBROBLAST; VIRUS CELL INTERACTION; VIRUS REPLICATION;

ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HLA-A2 ANTIGEN; HLA-B7 ANTIGEN; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERFERON-GAMMA; MUTAGENESIS; PHOSPHOPROTEINS; RNA-BINDING PROTEINS; VIRAL ENVELOPE PROTEINS; VIRAL MATRIX PROTEINS; VIRAL PROTEINS; VIRUS REPLICATION;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 67650710746     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.06.004     Document Type: Article

References (72)

1. Ahn K., Angulo A., Ghazal P., Peterson P.A., Yang Y., and Früh K. Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 10990-10995
2. Ahn K., Gruhler A., Galocha B., Jones T.R., Wiertz E.J., Ploegh H.L., Peterson P.A., Yang Y., and Früh K. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 6 (1997) 613-621
3. Andreoni M., Faircloth M., Vugler L., and Britt W.J. A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J. Virol. Methods 23 (1989) 157-167
4. Barel M.T., Pizzato N., van L.D., Bouteiller P.L., Wiertz E.J., and Lenfant F. Amino acid composition of alpha1/alpha2 domains and cytoplasmic tail of MHC class I molecules determine their susceptibility to human cytomegalovirus US11-mediated down-regulation. Eur. J. Immunol. 33 (2003) 1707-1716
5. Barel M.T., Ressing M., Pizzato N., van L.D., Le B.P., Lenfant F., and Wiertz E.J. Human cytomegalovirus-encoded US2 differentially affects surface expression of MHC class I locus products and targets membrane-bound, but not soluble HLA-G1 for degradation. J. Immunol. 171 (2003) 6757-6765
6. Barel M.T., Pizzato N., Le B.P., Wiertz E.J., and Lenfant F. Subtle sequence variation among MHC class I locus products greatly influences sensitivity to HCMV US2- and US11-mediated degradation. Int. Immunol. 18 (2006) 173-182
7. Barnes P.D., and Grundy J.E. Down-regulation of the class I HLA heterodimer and beta 2- microglobulin on the surface of cells infected with cytomegalovirus. J. Gen. Virol. 73 (1992) 2395-2403
8. Ben-Arieh S.V., Zimerman B., Smorodinsky N.I., Yaacubovicz M., Schechter C., Bacik I., Gibbs J., Bennink J.R., Yewdell J.W., Coligan J.E., Firat H., Lemonnier F., and Ehrlich R. Human cytomegalovirus protein US2 interferes with the expression of human HFE, a nonclassical class I major histocompatibility complex molecule that regulates iron homeostasis. J. Virol. 75 (2001) 10557-10562
9. Besold K., Frankenberg N., Pepperl-Klindworth S., Kuball J., Theobald M., Hahn G., and Plachter B. Processing and MHC class I presentation of human cytomegalovirus pp65-derived peptides persist despite gpUS2-11-mediated immune evasion. J. Gen. Virol. 88 (2007) 1429-1439
10. Böhm V., Simon C.O., Podlech J., Seckert C.K., Gendig D., Deegen P., Gillert-Marien D., Lemmermann N.A., Holtappels R., and Reddehase M.J. The immune evasion paradox: immunoevasins of murine cytomegalovirus enhance priming of CD8 T cells by preventing negative feedback regulation. J. Virol. 82 (2008) 11637-11650
11. Borst E.M., Hahn G., Koszinowski U.H., and Messerle M. Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J. Virol. 73 (1999) 8320-8329
12. Bouvier M. Accessory proteins and the assembly of human class I MHC molecules: a molecular and structural perspective. Mol. Immunol. 39 (2003) 697-706
13. Braud V.M., Tomasec P., and Wilkinson G.W. Viral evasion of natural killer cells during human cytomegalovirus infection. Curr. Top. Microbiol. Immunol. 269 (2002) 117-129
14. Brune W., Wagner M., and Messerle M. Manipulating cytomegalovirus genomes by BAC mutagensis: strategies and applications. In: Reddehase M.J. (Ed). Cytomegaloviruses: Molecular Biology and Immunology (2006), Caister Academic Press Ltd, Wymondham, Norfolk, U.K. 63-89
15. Chau N.H., Vanson C.D., and Kerry J.A. Transcriptional regulation of the human cytomegalovirus US11 early gene. J. Virol. 73 (1999) 863-870
16. Cherepanov P.P., and Wackernagel W. Gene disruption in Escherichia coli: TcR and KmR cassettes with the option of Flp-catalyzed excision of the antibiotic-resistance determinant. Gene 158 (1995) 9-14
17. Colberg-Poley A.M., Santomenna L.D., Harlow P.P., Benfield P.A., and Tenney D.J. Human cytomegalovirus US3 and UL36-38 immediate-early proteins regulate gene expression. J. Virol. 66 (1992) 95-105
18. Diamond D.J., York J., Sun J.Y., Wright C.L., and Forman S.J. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 90 (1997) 1751-1767
19. Dunn W., Chou C., Li H., Hai R., Patterson D., Stolc V., Zhu H., and Liu F. Functional profiling of a human cytomegalovirus genome. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 14223-14228
20. Elkington R., Walker S., Crough T., Menzies M., Tellam J., Bharadwaj M., and Khanna R. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J. Virol. 77 (2003) 5226-5240
21. Falk C.S., Mach M., Schendel D.J., Weiss E.H., Hilgert I., and Hahn G. NK cell activity during human cytomegalovirus infection is dominated by US2-11-mediated HLA class I down-regulation. J. Immunol. 169 (2002) 3257-3266
22. Fleckenstein B., Müller I., and Collins J. Cloning of the complete human cytomegalovirus genome in cosmids. Gene 18 (1982) 39-46
23. Frankenberg N., Pepperl-Klindworth S., Meyer R.G., and Plachter B. Identification of a conserved HLA-A2-restricted decapeptide from the IE1 protein (pUL123) of human cytomegalovirus. Virology 295 (2002) 208-216
24. Furman M.H., Dey N., Tortorella D., and Ploegh H.L. The human cytomegalovirus US10 gene product delays trafficking of major histocompatibility complex class I molecules. J. Virol. 76 (2002) 11753-11756
25. Gallez-Hawkins G., Villacres M.C., Li X., Sanborn M.C., Lomeli N.A., and Zaia J.A. Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response. J. Virol. 77 (2003) 4457-4462
26. Gewurz B.E., Gaudet R., Tortorella D., Wang E.W., Ploegh H.L., and Wiley D.C. Antigen presentation subverted: structure of the human cytomegalovirus protein US2 bound to the class I molecule HLA-A2. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6794-6799
27. Gewurz B.E., Wang E.W., Tortorella D., Schust D.J., and Ploegh H.L. Human cytomegalovirus US2 endoplasmic reticulum-lumenal domain dictates association with major histocompatibility complex class I in a locus-specific manner. J. Virol. 75 (2001) 5197-5204
28. Gilbert M.J., Riddell S.R., Li C.R., and Greenberg P.D. Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. J. Virol. 67 (1993) 3461-3469
29. Gillespie G.M., Wills M.R., Appay V., O'Callaghan C., Murphy M., Smith N., Sissons P., Rowland-Jones S., Bell J.I., and Moss P.A. Functional heterogeneity and high frequencies of cytomegalovirus- specific CD8(+) T lymphocytes in healthy seropositive donors. J. Virol. 74 (2000) 8140-8150
30. Heemels M.T., and Ploegh H. Generation, translocation, and presentation of MHC class I-restricted peptides. Annu. Rev. Biochem. 64 (1995) 463-491
31. Hegde N.R., Tomazin R.A., Wisner T.W., Dunn C., Boname J.M., Lewinsohn D.M., and Johnson D.C. Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation. J. Virol. 76 (2002) 10929-10941
32. Jones T.R., and Muzithras V.P. Fine mapping of transcripts expressed from the US6 gene family of human cytomegalovirus strain AD169. J. Virol. 65 (1991) 2024-2036
33. Jones T.R., and Sun L. Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains. J. Virol. 71 (1997) 2970-2979
34. Jones T.R., Hanson L.K., Sun L., Slater J.S., Stenberg R.M., and Campbell A.E. Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains. J. Virol. 69 (1995) 4830-4841
35. Jones T.R., Wiertz E.J., Sun L., Fish K.N., Nelson J.A., and Ploegh H.L. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 11327-11333
36. Khan N., Bruton R., Taylor G.S., Cobbold M., Jones T.R., Rickinson A.B., and Moss P.A. Identification of cytomegalovirus-specific cytotoxic T lymphocytes in vitro is greatly enhanced by the use of recombinant virus lacking the US2 to US11 region or modified vaccinia virus Ankara expressing individual viral genes. J. Virol. 79 (2005) 2869-2879
37. Kollert-Jöns A., Bogner E., and Radsak K. A 15-kilobase-pair region of the human cytomegalovirus genome which includes US1 through US13 is dispensable for growth in cell culture. J. Virol. 65 (1991) 5184-5189
38. Lee E.C., Yu D., Martinez d.V., Tessarollo L., Swing D.A., Court D.L., Jenkins N.A., and Copeland N.G. A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. Genomics 73 (2001) 56-65
39. Lilley B.N., and Ploegh H.L. A membrane protein required for dislocation of misfolded proteins from the ER. Nature 429 (2004) 834-840
40. Lilley B.N., and Ploegh H.L. Viral modulation of antigen presentation: manipulation of cellular targets in the ER and beyond. Immunol. Rev. 207 (2005) 126-144
41. Llano M., Guma M., Ortega M., Angulo A., and Lopez-Botet M. Differential effects of US2, US6 and US11 human cytomegalovirus proteins on HLA class Ia and HLA-E expression: impact on target susceptibility to NK cell subsets. Eur. J. Immunol. 33 (2003) 2744-2754
42. Loenen W.A., Bruggeman C.A., and Wiertz E.J. Immune evasion by human cytomegalovirus: lessons in immunology and cell biology. Semin. Immunol. 13 (2001) 41-49
43. Loureiro J., Lilley B.N., Spooner E., Noriega V., Tortorella D., and Ploegh H.L. Signal peptide peptidase is required for dislocation from the endoplasmic reticulum. Nature 441 (2006) 894-897
44. Manley T.J., Luy L., Jones T., Boeckh M., Mutimer H., and Riddell S.R. Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection. Blood 104 (2004) 1075-1082
45. Mersseman V., Besold K., Reddehase M.J., Wolfrum U., Strand D., Plachter B., and Reyda S. Exogenous introduction of an immunodominant peptide from the non-structural IE1 protein of human cytomegalovirus into the MHC class I presentation pathway by recombinant dense bodies. J. Gen. Virol. 89 (2008) 369-379
46. Mersseman V., Bohm V., Holtappels R., Deegen P., Wolfrum U., Plachter B., and Reyda S. Refinement of strategies for the development of a human cytomegalovirus dense body vaccine. Med. Microbiol. Immunol. 197 (2008) 97-107
47. Miyahira Y., Murata K., Rodriguez D., Rodriguez J.R., Esteban M., Rodrigues M.M., and Zavala F. Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J. Immunol. Methods 181 (1995) 45-54
48. Mocarski E.S. Immune escape and exploitation strategies of cytomegaloviruses: impact on and imitation of the major histocompatibility system. Cell. Microbiol. 6 (2004) 707-717
49. Mocarski E.S., Shenk T., and Pass R.F. Cytomegaloviruses. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology (2007), Lippincott Williams & Wilkins, Philadelphia 2701-2772
50. Noriega V.M., and Tortorella D. Human cytomegalovirus-encoded immune modulators partner to downregulate major histocompatibility complex class I molecules. J. Virol. 83 (2009) 1359-1367
51. Plachter B., Britt W.J., Vornhagen R., Stamminger T., and Jahn G. Analysis of proteins encoded by IE-regions 1 and 2 of human cytomegalovirus using monoclonal antibodies generated against recombinant antigens. Virology 193 (1993) 642-652
52. Powers C., DeFilippis V., Malouli D., and Früh K. Cytomegalovirus immune evasion. Curr. Top. Microbiol. Immunol. 325 (2008) 333-360
53. Reddehase M.J. Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat. Rev., Immunol. 2 (2002) 831-844
54. Reddehase M.J., Mutter W., Münch K., Bühring H.J., and Koszinowski U.H. CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J. Virol. 61 (1987) 3102-3108
55. Rehm A., Engelsberg A., Tortorella D., Korner J., Lehmann I., Ploegh H.L., and Hopken U.E. Human cytomegalovirus gene products US2 and US11 differ in their ability to attack major histocompatibility class I heavy chains in dendritic cells. J. Virol. 76 (2002) 5043-5050
56. Retiere C., Prod'homme V., Imbert-Marcille B.M., Bonneville M., Vie H., and Hallet M.M. Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp65 or IE1 proteins: a tool to study the fine specificity of the antiviral response. J. Virol. 74 (2000) 3948-3952
57. Schmolke S., Drescher P., Jahn G., and Plachter B. Nuclear targeting of the tegument protein pp65 (UL83) of human cytomegalovirus: an unusual bipartite nuclear localization signal functions with other portions of the protein to mediate its efficient nuclear transport. J. Virol. 69 (1995) 1071-1078
58. Schust D.J., Tortorella D., Seebach J., Phan C., and Ploegh H.L. Trophoblast class I major histocompatibility complex (MHC) products are resistant to rapid degradation imposed by the human cytomegalovirus (HCMV) gene products US2 and US11. J. Exp. Med. 188 (1998) 497-503
59. Simon C.O., Holtappels R., Tervo H.M., Böhm V., Däubner T., Oehrlein-Karpi S.A., Kühnapfel B., Renzaho A., Strand D., Podlech J., Reddehase M.J., and Grzimek N.K.A. CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation. J. Virol. 80 (2006) 10436-10456
60. Sinzger C., Grefte A., Plachter B., Gouw A.S.H., The T.H., and Jahn G. Fibroblasts, epithelial cells, endothelial cells and smooth muscle cells are major targets of human cytomegalovirus infection in-vivo. J. Gen. Virol. 76 (1995) 741-750
61. Tirabassi R.S., and Ploegh H.L. The human cytomegalovirus US8 glycoprotein binds to major histocompatibility complex class I products. J. Virol. 76 (2002) 6832-6835
62. Tomazin R., Boname J., Hegde N.R., Lewinsohn D.M., Altschuler Y., Jones T.R., Cresswell P., Nelson J.A., Riddell S.R., and Johnson D.C. Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells. Nat. Med. 5 (1999) 1039-1043
63. Tortorella D., Gewurz B.E., Furman M.H., Schust D.J., and Ploegh H.L. Viral subversion of the immune system. Annu. Rev. Immunol. 18 (2000) 861-926
64. Townsend A., Ohlen C., Bastin J., Ljunggren H.G., Foster L., and Karre K. Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature 340 (1989) 443-448
65. Waller E.C., McKinney N., Hicks R., Carmichael A.J., Sissons J.G., and Wills M.R. Differential costimulation through CD137 (4-1BB) restores proliferation of human virus-specific "effector memory" (CD28(-) CD45RA(HI)) CD8(+) T cells. Blood 110 (2007) 4360-4366
66. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., and Riddell S.R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333 (1995) 1038-1044
67. Weekes M.P., Wills M.R., Mynard K., Carmichael A.J., and Sissons J.G. The memory cytotoxic T-lymphocyte (CTL) response to human cytomegalovirus infection contains individual peptide-specific CTL clones that have undergone extensive expansion in vivo. J. Virol. 73 (1999) 2099-2108
68. Wiertz E.J., Jones T.R., Sun L., Bogyo M., Geuze H.J., and Ploegh H.L. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 84 (1996) 769-779
69. Wiertz E.J., Tortorella D., Bogyo M., Yu J., Mothes W., Jones T.R., Rapoport T.A., and Ploegh H.L. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 384 (1996) 432-438
70. Wills M.R., Carmichael A.J., Mynard K., Jin X., Weekes M.P., Plachter B., and Sissons J.G. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65- specific CTL. J. Virol. 70 (1996) 7569-7579
71. Yewdell J.W., and Bennink J.R. Cut and trim: generating MHC class I peptide ligands. Curr. Opin. Immunol. 13 (2001) 13-18
72. Yu D., Smith G.A., Enquist L.W., and Shenk T. Construction of a self-excisable bacterial artificial chromosome containing the human cytomegalovirus genome and mutagenesis of the diploid TRL/IRL13 gene. J. Virol. 76 (2002) 2316-2328